Clinical Evaluation of Low Sodium Peritoneal Dialysis (PD) Solution on Hypertensive Patients Treated With PD (PDOne)
26. Februar 2015 aktualisiert von: Fresenius Medical Care Deutschland GmbH
Multicentric, Parallel, Controlled, Randomized, Single-blind Clinical Evaluation of New Low Sodium Peritoneal Dialysis Solution on Patients With Hypertension Treated With Continuous Ambulatory or Automated Peritoneal Dialysis
The aim of this study is to assess the superiority of the new low sodium peritoneal dialysis (PD) solution PDsol 12 in comparison with a conventional, already marketed solution, Gambrosol trio 40, in the treatment of the hypertensive peritoneal dialysis patients with aim to decrease hypertension and to improve the sodium/water balance.
Studienübersicht
Status
Abgeschlossen
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Hypertension as well as sodium and water retention are common in end-stage renal disease patients on peritoneal dialysis and expose patients to left ventricular hypertrophy and increase cardiovascular mortality.
Moreover the poor control of dry weight and sodium/water balance results in increased morbidity. A previous low sodium study and computer simulations show that sodium removal can be improved with a low sodium fluid, which allows achieving a negative sodium balance without altering water balance.
The aim of this study is to assess whether treatment with one low sodium bag can substitute for one isotonic glucose bag every day in order to reduce the blood pressure and/or medication for hypertension, defined as the primary endpoint.
In order to evaluate the main criteria, blood pressure, a 24hours Ambulatory Blood Pressure Monitoring (ABPM) will be performed twice during the study, at Baseline and at 8 weeks of treatment, according to the EMEA guidance recommendations for anti-hypertensive treatments. In addition, the self measurement of blood pressure will be performed by patients at home during three consecutive days before each visit as well as in case of symptoms of hypotension.
The study is designed in three periods:
- Run-in period during 1 month: a reference product Gambrosol Trio 40, one bag/ day will be used by all patients. This period is dedicated to train the patient in using of study product, to stabilize the patient in the PD treatment and to randomize the patient, by performing the 24h ABPM.
- Efficacy & Safety period during 6 months: each patient will be treated with one of two product : PDsol 12 (studied product) or Gambrosol Trio 40 (reference product) during 6 months. The aim of this period is to evaluate the efficacy and long-term tolerance of new PD fluid.
- Follow-up period during 2 months: without treatment. This period is dedicated to ensure the safety of the patients after the study product treatment was stopped and to obtain the information about the reversibility of product effect.
Studientyp
Interventionell
Einschreibung (Voraussichtlich)
140
Phase
- Phase 3
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienorte
-
-
-
Hannover, Deutschland, 30659
- KfH-Nierenzentrum am Krankenhaus Oststadt
-
Heidelberg, Deutschland
- university Hospital of Heidelberg
-
Köln, Deutschland, 51109
- KfH-Nierenzentrum
-
Offenburg, Deutschland
- Nephrology center Offenburg
-
Passau, Deutschland, 94032
- KfH-Nierenzentrum
-
Stuttgart, Deutschland
- PHV - Nephrologisches Zentrum Stuttgart
-
Trier, Deutschland, 54292
- KfH-Nierenzentrum Krankenhaus der Barmherzigen Brüder
-
-
-
-
-
Copenhagen, Dänemark
- Rigshospitalet
-
-
-
-
-
Besançon, Frankreich, 25000
- CHU Saint-Jacques
-
Caen, Frankreich, 14033
- CHRU
-
Chambery, Frankreich
- Hospital of Chambéry
-
Colmar, Frankreich
- CH Colmar
-
Irigny, Frankreich
- Calydial Dialysis Center
-
Paris, Frankreich
- Bichat-Claude Bernard Hospital
-
Reims, Frankreich, 51726
- ARPDD
-
Strasbourg, Frankreich
- CHRU de Strasbourg
-
-
-
-
-
Borås, Schweden
- Södra Älvborgsläns Hospital
-
Göteborg, Schweden
- University Hospital of Sahlgrenska
-
Lund, Schweden
- University Hospital of Lund
-
Malmö, Schweden
- University Hospital of Malmö
-
Skövde, Schweden
- Skarborgs Hospital
-
Stockholm, Schweden, 14186
- Karolinska University Hospital
-
Trollhättan, Schweden
- Norra Älvsborgs Hospital
-
-
-
-
-
Birmingham, Vereinigtes Königreich, B9 5SS
- Birmingham Heartlands Hospital
-
Bristol, Vereinigtes Königreich, BS10 5NB
- Southmead Hospital
-
London, Vereinigtes Königreich, E1 1BB
- The Royal London Hospital
-
Shrewsbury, Vereinigtes Königreich, SY3 8XQ
- Royal Shrewsbury Hospital
-
Stoke on Trent, Vereinigtes Königreich, ST47LN
- University of North Staffordshire - Renal Medicine - Royal Infirmary
-
Wolverhampton, Vereinigtes Königreich, WV10 0QP
- Wolverhampton New Cross Hospital
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
18 Jahre und älter (Erwachsene, Älterer Erwachsener)
Akzeptiert gesunde Freiwillige
Nein
Studienberechtigte Geschlechter
Alle
Beschreibung
Inclusion Criteria:
- Chronic renal failure
- Stable patients on PD treatment
- Treatment at the study site for at least three months
- Treated in a CAPD program with a minimum of 3 bag exchanges with 6 or 7 days per week including at least one with duration of 4-6 hours, and at least one low strength bag per day, or in an APD program with at least one daytime exchange with duration of 4-6 hours using one low strength bag
- Hypertensive patients with high blood pressure at inclusion visit (Office SBP ≥ 140 and/or DBP ≥ 90 mmHg) or hypertensive patients receiving anti hypertensive medication including diuretics, disregarded blood pressure values
- Patients aged 18 years or more
- Written consent to participate in the study (informed consent)
- Able to use a three-compartment bag
- Life expectancy and expected technical survival ≥ 9 months
Exclusion Criteria:
- Low blood pressure (Office sitting SBP ≤ 120 mmHg and confirmed by ABPM < or = to 105 mean 24h SBP)
- Orthostatic hypotension defined as Systolic OBP with a drop of > 20mmHg and symptomatic after standing for at least 1 minute
- Natremia < 130 mmol/l, after two consecutive measurements
- Chronic arrhythmia
- Pregnancy or lactation
- Participation in other studies during the study period which may affect the outcome of the present study
- Peritonitis within one month prior to the study start
- Exit site and /or tunnel infection
- Patients unable to tolerate 2 L bag exchanges
- Patients on non-compatible PD system
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: PDsol 12
Treatment with a peritoneal dialysis solution containing a low concentration of sodium.
|
Treatment with one bag per day during 6 months
|
|
Aktiver Komparator: Gambrosol trio 40
Treatment with the peritoneal dialysis solution Gambrosol trio 40 isotonic bag (1.5%)
|
Treatment with one bag per day during 6 months
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
The primary criterion is the ambulatory 24 h mean systolic blood pressure measurement and drug doses management after 2 months of treatment compared to Baseline.
Zeitfenster: At the beginning and after 8 weeks of treatment
|
At the beginning and after 8 weeks of treatment
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Measurement of Residual Renal Function
Zeitfenster: At the beginning, at two and six months of treatment
|
At the beginning, at two and six months of treatment
|
|
Follow-up of frequency of hyponatremia, of AE and SAE
Zeitfenster: During whole period of the study
|
During whole period of the study
|
|
Assessment of changes in sodium removal
Zeitfenster: At the beginning and at two months of treatment
|
At the beginning and at two months of treatment
|
|
Assessment of decrease in total body water (extra and intra cellular water)and of the body weigh changes
Zeitfenster: At the beginning, at two and at six months of treatment
|
At the beginning, at two and at six months of treatment
|
|
Measurement of 24hours peritoneal clearance
Zeitfenster: At the beginning and at 2 months of treatment
|
At the beginning and at 2 months of treatment
|
|
Office systolic and diastolic blood pressure measurement at month 2 and 6 versus T0
Zeitfenster: At the beginning, at two and six months of treatment
|
At the beginning, at two and six months of treatment
|
|
Office systolic and diastolic blood pressure measurement during follow up period
Zeitfenster: End of treatment, follow-up period
|
End of treatment, follow-up period
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Ermittler
- Studienstuhl: Simon Davies, Prof, University Hospital of North Staffordshire, Stoke-on-Trent, UK
- Studienstuhl: Bengt Rippe, Prof, Lund University
- Studienstuhl: Börje Haraldsson, Prof, Sahlgrenska University Hospital, Göteborg, Sweden
- Studienstuhl: François Vrtovsnik, Prof, Bichat -Claude Bernard Hospital, Paris, France
- Studienstuhl: Vedat Schwenger, Dr, Universitätsklinik University Hospital, Heidelberg, Germany
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn
1. Oktober 2008
Primärer Abschluss (Tatsächlich)
1. Dezember 2014
Studienabschluss (Tatsächlich)
1. Dezember 2014
Studienanmeldedaten
Zuerst eingereicht
18. November 2008
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
19. November 2008
Zuerst gepostet (Schätzen)
20. November 2008
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
27. Februar 2015
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
26. Februar 2015
Zuletzt verifiziert
1. September 2014
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 1449 (CSL Behring)
- EudraCT 2007-005365-35
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .